Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Structural biology of SARS-CoV-2 and implications for therapeutic development
H Yang, Z Rao - Nature Reviews Microbiology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Abstract Omicron (B. 1.1. 529), the most heavily mutated SARS-CoV-2 variant so far, is
highly resistant to neutralizing antibodies, raising concerns about the effectiveness of …
highly resistant to neutralizing antibodies, raising concerns about the effectiveness of …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: an …
X Xu, W Jiang, L Chen, Z Xu, Q Zhang… - Clinical and …, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has …
syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has …
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
L Zhang, L Cao, XS Gao, BY Zheng… - National Science …, 2021 - academic.oup.com
Mutations and transient conformational movements of the receptor binding domain (RBD)
that make neutralizing epitopes momentarily unavailable present immune escape routes for …
that make neutralizing epitopes momentarily unavailable present immune escape routes for …
An engineered bispecific human monoclonal antibody against SARS-CoV-2
Z Li, S Li, G Zhang, W Peng, Z Chang, X Zhang… - Nature …, 2022 - nature.com
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …